AlphAIAlphAI — Financial news for AI agents
rttnews.com$HRTX

Heron Therapeutics Reports Q3 Revenue Of $35.3 Mln; Agrees To Sell Assets To CorMedix

Heron Therapeutics (HRTX) reported Q3 2026 revenue of $35.3M, down from $38.2M YoY. Acute Care revenue grew 22.5% YoY, while Oncology Supportive Care declined. Heron agreed to sell all assets to CorMedix (CRMD) for $145M cash, 14.58M CRMD shares, and up to $55M in earn-outs. The deal is expected to close in Q1 2027. HRTX and CRMD shares are up 30.00% and 2.07% respectively.

Original reporting
rttnews.com
Published Nov 9, 2026, 3:16 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 9, 2026, 3:21 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefMergers & acquisitions
Primary signal
$HRTX
Bearish
high confidence
Mentioned
$HRTX · $CRMD
Relevance
7/10
AlphAI data visualization · based on rttnews.com
Decision brief

The 30-second read

$HRTXBearishHigh
01

Why it matters

The transaction provides a liquidity event for Heron and expands CorMedix's product portfolio, influencing valuation expectations for both companies.

02

Market read

A material M&A deal for two micro‑cap biotech firms, offering immediate price catalysts and strategic repositioning.

03

What to watch

Potential regulatory review of the asset transfer and the earn‑out structure could delay value realization.

Relevance 7/10Novelty 8/10Timing: pre‑market today

Background

Heron Therapeutics reported Q3 2026 revenue of $35.3M and announced a definitive asset sale to CorMedix, detailing cash and share consideration.

Company-level read

Ticker impact

$HRTXBearishHigh confidence
Context

Heron Therapeutics disclosed a definitive agreement to sell substantially all assets to CorMedix, including a $145M cash component and earn‑out potential.

Expected impact

likely upward pressure as market prices in the cash consideration and strategic exit.

Evidence & confidence

The transaction provides immediate liquidity and a premium to current valuation, a material catalyst for a micro‑cap.

$CRMDNeutralMedium confidence
Context

CorMedix Therapeutics announced it will acquire Heron's assets, issuing 14.58M shares valued at $77.6M as part of the deal.

Expected impact

potential modest downside as market absorbs share issuance and integration risk.

Evidence & confidence

The share issuance dilutes existing holders; impact depends on post‑deal synergies.

Market effects

Sector

Consolidation in the acute‑care oncology niche may prompt other small biotech M&A activity.

Regional

Limited to US biotech sector; no broader regional effect.

Global

Minor global impact; primarily relevant to investors in niche biotech stocks.

Counterpoint

What could challenge this read

Deal could overvalue Heron's assets; integration risk may erode value, suggesting a short bias on CRMD.

Key entities

  • company
    Heron Therapeutics, Inc.

    Commercial‑stage biotech selling its assets.

  • company
    CorMedix Therapeutics

    Acquirer of Heron's assets.

Read at source← All news

Also covered by

1 outlet

Related articles

$CRMDHighAI 8/10

CorMedix to Acquire Heron Assets, Adding Four Products and Targeting Up to $60 Million in Savings

CorMedix (CRMD) will acquire assets from Heron, adding four products and aiming for $60M in savings. Heron may receive up to $55M in additional payments tied to ZYNRELEF's 2028 sales. CorMedix will fund the deal with $70M in cash and a $150M loan. Heron's convertible debt holders will convert debt into CorMedix stock. CorMedix plans to relaunch SUSTOL and focus on APONVIE, with a potential FDA approval for an undisclosed injectable product in 2027.

finance.yahoo.com
$CRMDHighAI 8/10

CorMedix stock maintains outperform rating on Heron acquisition

Citizens reiterated an Outperform rating and $19.00 price target on CorMedix (CRMD). The company agreed to acquire Heron Therapeutics' assets for $225M, expecting to close in Q1 2027. CRMD reported Q2 2026 earnings of $0.29/share on $101.9M revenue, beating estimates. Analysts highlight strategic fit, revenue diversification, and strong financials.

investing.com
$CRMDHighAI 9/10

CorMedix, Heron Strike $223 Mln Upfront Asset Deal; Closing Expected In 2027; Stock Up

CorMedix (CRMD) will acquire Heron's (HRTX) assets for $222.6M upfront, including cash and stock, with potential earn-outs. The deal adds four commercial-stage products to CorMedix's portfolio, expected to close in 2027. CorMedix anticipates earnings accretion and cost synergies, while Heron will remain public and evaluate future opportunities. Both stocks rose on the news.

rttnews.com
$CRMDHighAI 8/10

CorMedix stock gains as Heron deal adds four products

CorMedix (CRMD) shares rose 4.5% premarket after announcing a $222.6M deal to acquire Heron Therapeutics' (HRTX) assets, including four commercial products. CorMedix will pay $145M cash and issue 14.6M shares. The deal is expected to close in Q1 2027 and be immediately accretive to earnings, with pro forma 2026 revenue estimated at $465M-$490M.

investing.com